Investigating the relationship between embryonic glucose homeostasis and neural tube closure
Active Project Grant Awarded Last action
- Award ID
- F31HD118805
- Recipient
-
The Regents Of The University Of Colorado UEI SPVKK1RC2MZ3
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $170,918
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date 44% complete
- Place of performance
- Boulder, CO 80303, USA
Award details come from USAspending.gov.
About this award
The National Institute of Child Health and Human Development awarded The Regents of the University of Colorado $170,918 on September 27, 2025, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to investigate the relationship between embryonic glucose homeostasis and neural tube closure. The project runs through March 31, 2028, with performance in Boulder, Colorado.
The research examines how insulin receptor substrate 1 (IRS-1) mediates embryonic glucose homeostasis and its connection to neural tube defect risk, with particular focus on the embryonic response to elevated glucose exposure associated with maternal diabetes. The study uses mouse neural progenitor cells to investigate two specific aims: the role of IRS-1 in cellular glucose consumption dynamics and the downstream effects of IRS-1 perturbation on glucose homeostasis and neural tube closure. The work is conducted in collaboration with the Gleeson Lab at UC San Diego and builds on clinical observations that multiple patients with neural tube defects carry mutations in IRS1. This project grant funds an individual investigator's research training and doctoral-level research in the context of understanding congenital developmental differences that affect approximately one to two per thousand pregnancies globally.
Description
- Abstract
- Neural tube defects (NTDS) occur in ~1-2 in 1000 pregnancies globally every year and constitute one of the top three most common congenital developmental differences in the world. An embryo with an NTD develops with an area of partially enclosed or completely exposed central nervous tissue, which can lead to complications both during pregnancy and after birth. Some NTDS are so severe they lead to lethality, and even milder forms of NTDS lead to a decreased quality of life. NTDS can have many negative consequences for the people they affect, and improving identification of pregnancies that are at risk for an NTD would benefit many people around the world. One known NTD risk factor is maternal diabetes, which exposes the embryo to elevated levels of glucose. The relevance of glucose to NTDS is one of the factors that makes insulin receptor substrate 1 (IRS-1) an attractive candidate for investigation as a potential player in NTD risk. In addition to the role of IRS-1 in mediating glucose uptake, glucose utilization, and cell growth, multiple patients with NTDS have mutations in IRS1 (collaboration with the gleeson lab, ucsd). These pieces of evidence focus my proposed project on IRS-1 and its intersections with maternal diabetes and embryonic glucose response. Much work has been done on glucose from the maternal perspective, but little is known about glucose homeostasis or the role of IRS-1 in the embryo. This study aims to use IRS-1 to clarify the relationship between NTD risk and the embryonic response to environmental glucose. By understanding how perturbing IRS-1 levels can dysregulate glucose homeostasis and lead to NTDS, we can improve identification of pregnancies at risk for NTDS. To achieve these goals, the proposed study has two aims. Specific aim 1 will investigate the role of IRS-1 in cellular glucose consumption dynamics using mouse neural progenitor cell lines and primary cells with a genetic knock-out of the IRS1 gene. Specific aim 2 will examine IRS-1 loss using an established IRS1 knockout mouse line. Embryos from this model will be cultured and live-imaged EX utero to dynamically assess the effects of IRS-1 loss on the morphology of the neural tube as IT closes. To understand potential interactions between maternal diabetes and IRS1 loss, female mice from this line will also be treated with streptozotocin to induce diabetes, and NTD incidence in their offspring will be measured. All experiments will be conducted in the niswander lab, which is part of the molecular, cellular, and developmental biology department at the university of colorado boulder. Both the lab and department provide excellent resources including a supportive environment, quality equipment, and a wealth of knowledge from experienced scientists. These resources will support my journey towards my career goal of becoming an independent research scientist in academia, as well as my intermediary training goals of accumulating technical skills in developmental biology, improving my science communication skills, and mentoring future scientists.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $43,652 | |
| Amendment | $564 | |
| Amendment | $42,234 | |
| Amendment | $42,234 | |
| Amendment | $0 | |
| Amendment | $42,234 | |
| Original award | $0 |
Quick answers
Who received award F31HD118805?
F31HD118805 was awarded to The Regents Of The University Of Colorado by National Institute of Child Health and Human Development (National Institutes of Health) on September 27, 2025.
How much is award F31HD118805 worth?
$170,918 has been obligated on F31HD118805.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award